Status:
COMPLETED
Phase I, Exploratory, Single Centre, Single Oral Dose AZD9668 and Intravenous Microdose of [C14] AZD9668, Healthy Subject
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
MALE
18-65 years
Phase:
PHASE1
Brief Summary
The primary objective of this study is to assess the absolute bioavailability and to evaluate pharmacokinetic parameters of a single oral dose and a radiolabelled intravenous microdose of \[14C\]AZD96...
Detailed Description
This is an exploratory study to assess the absolute bioavailability of a single oral dose of AZD9668 with respect to an intra-venous microdose of \[14C\]AZD9668 in healthy male subjects.
Eligibility Criteria
Inclusion
- Provision of signed and dated, written informed consent prior to any study specific procedures
- Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weight at least 50 kg and no more than 100 kg.
Exclusion
- Any clinically significant disease or disorder
- Any clinically significant abnormalities at screening examination
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01161355
Start Date
June 1 2010
End Date
June 1 2010
Last Update
February 9 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Ruddington, Nottingham, United Kingdom
2
Research Site
London, United Kingdom